公开(公告)号：US10918717B2

公开(公告)日：2021-02-16

申请号：US15544335

申请日：2016-01-15

Applicant: GREEN CROSS CORPORATION

Inventor： Yong Woon Choi ,  Yoo Hoon Kim ,  Jungsub Choi

IPC: A61K39/395 ,  C07K16/28 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26 ,  C07K14/71

Abstract: The present invention provides a pharmaceutical formulation comprising an anti-epidermal growth factor receptor (EGFR) antibody. The pharmaceutical formulation has low turbidity, without showing aggregation or particle formation, even under accelerated conditions, and exhibits good stability. Therefore, the pharmaceutical formulation can be effectively used for the treatment of disorders such as cancer.

公开(公告)号：US10851175B2

公开(公告)日：2020-12-01

申请号：US15762885

申请日：2016-09-23

Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH ,  GREEN CROSS CORPORATION

Inventor： Dong-Sik Kim ,  Eun Jung Song ,  Mijung Lee ,  Eun-Hee Lee ,  Miyoung Oh ,  Jae Chan Park ,  Kisu Kim ,  Sujeong Kim ,  Hyung-Kwon Lim ,  Kyuhyun Lee ,  Jongwha Won ,  Soongyu Choi ,  Young Seoub Park

IPC: C07K16/18 ,  C07K16/30 ,  C07K16/28

Abstract: The present invention relates to an antibody specifically bound to mesothelin (MSLN), a nucleic acid encoding the antibody, a vector and a host cell including the nucleic acid, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumor including the antibody as an active ingredient. The antibody specifically bound to the mesothelin according to the present invention has high affinity and specificity to an antigen, such that it is possible to develop an antibody effectively usable for treatment or diagnosis of cancer or tumor diseases.

公开(公告)号：US10174299B2

公开(公告)日：2019-01-08

申请号：US15812851

申请日：2017-11-14

Applicant: GREEN CROSS CORPORATION ,  MediGeneBio Corporation

Inventor： Thong-Gyu Jin ,  Yo Kyung Chung ,  Sang Hoon Paik ,  Yoo Chang Park ,  Jinwook Seo ,  Yong Woon Choi ,  Jong Mun Son ,  Yong-Chul Kim

IPC: C12N9/16 ,  A61K38/46 ,  A61K9/00 ,  A61K47/02 ,  A61K47/26

Abstract: A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter Syndrome.

公开(公告)号：US20180030424A1

公开(公告)日：2018-02-01

申请号：US15223647

申请日：2016-07-29

Applicant: GREEN CROSS CORPORATION

Inventor： Sy LEE ,  Sung-Ick PARK

IPC: C12N9/16

CPC classification number: C12N9/16 ,  A61K38/00 ,  C12Y301/06013

Abstract: Provided is a modified iduronate-2-sulfatase (IDS) gene constructed by inserting the nucleotide of SEQ ID NO: 2 into a wild-type IDS gene. In addition to being negatively charged, the improved IDS enzyme encoded by the modified gene exhibits a sufficient retention time in blood to target the bone, so that it is more effective for treating Hunter syndrome.

公开(公告)号：US09856216B2

公开(公告)日：2018-01-02

申请号：US15134987

申请日：2016-04-21

Applicant: GREEN CROSS CORPORATION

Inventor： Soongyu Choi ,  Eun-Jung Park ,  Hee Jeong Seo ,  Younggyu Kong ,  Ickhwan Son ,  Sang-ho Ma ,  Man-Young Cha ,  Mi-Soon Kim ,  Kisoo Park

IPC: C07D209/14 ,  C07D209/48 ,  C07D209/46 ,  C07D417/04 ,  C07D403/04 ,  C07D401/04 ,  C07D403/14 ,  C07D409/12 ,  C07D405/12 ,  C07D409/04 ,  C07D413/04 ,  C07D409/14 ,  C07D403/12 ,  C07D405/06 ,  C07D409/06 ,  C07D471/04 ,  C07D217/24 ,  C07D401/12

CPC classification number: C07D209/46 ,  C07D209/48 ,  C07D217/24 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04

Abstract: Provided is a compound of formula (I) as a TNIK (Traf2- and NCK-interacting kinase), IKKε (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the compound according to the present invention effectively inhibits TNIK, IKKε and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

公开(公告)号：US20170189473A1

公开(公告)日：2017-07-06

申请号：US15314324

申请日：2015-05-29

Applicant: GREEN CROSS CORPORATION ,  PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION

Inventor： Bok Luel LEE ,  Min Ja LEE ,  Jong-Ho LEE ,  Min Young SEONG ,  Dong Ho AHN ,  Kazue TAKAHASHI ,  Kenji KUROKAWA

IPC: A61K38/14 ,  C12P21/00

CPC classification number: A61K38/14 ,  A61K38/17 ,  C12P21/005

Abstract: A composition containing wall teichoic acid-attached peptidoglycan (WTA-PGN) as an active ingredient, a method for preventing or treating Staphylococcus aureus infectious diseases using the composition, and a method for preparing a soluble WTA-PGN which can be used as an active ingredient in the composition are provided. The composition of the present invention can be effectively used for preventing or treating Staphylococcus aureus infectious diseases by opsonophagocytosis due to antigen-antibody reaction and neutrophil-mediated phagocytosis due to T cell activation at the early stage of infection.

公开(公告)号：US20170145107A1

公开(公告)日：2017-05-25

申请号：US15425413

申请日：2017-02-06

Applicant: GREEN CROSS CORPORATION ,  MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE

Inventor： Se-Ho KIM ,  Kwang-Won HONG ,  Ki-Hwan CHANG ,  Min-soo KIM ,  Mi-jung LEE ,  Jong-hwa WON ,  Min-Kyu HUR ,  Hyun-Soo CHO ,  Ji-Ho YOO

IPC: C07K16/30 ,  C12N15/10 ,  A61K39/00

CPC classification number: C07K16/3046 ,  A61K39/0005 ,  A61K39/0011 ,  A61K2039/53 ,  C07K16/2863 ,  C07K2317/10 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/567 ,  C07K2317/76 ,  C12N15/1037 ,  G01N33/57492 ,  G01N2333/71

Abstract: Disclosed are epitopes of the epidermal growth factor receptor (EGFR) and the use thereof. The epitopes are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (EGF). Therefore, vaccine compositions comprising the epitopes or compositions comprising antibodies to the epitopes may efficiently block a signal transduction caused by binding of EGF and EGRF, and thus can be highly valuably used in treating various diseases such as cancer. An antibody bound to the epitopes of the present invention may efficiently inhibit binding of various EGFR ligands such as not only EGF but also TGF-α, AR, BTC, EPR and HB-EGF, with EGFR, and therefore can be used in treating various diseases resulting from an activation of EGFR caused by binding not only with EGF but also with other EGFR ligands.

公开(公告)号：US20160311772A1

公开(公告)日：2016-10-27

申请号：US15134987

申请日：2016-04-21

Applicant: GREEN CROSS CORPORATION

Inventor： Soongyu CHOI ,  Eun-Jung PARK ,  Hee Jeong SEO ,  Younggyu KONG ,  Ickhwan SON ,  Sang-ho MA ,  Man-Young CHA ,  Mi-Soon KIM ,  Kisoo PARK

IPC: C07D209/46 ,  C07D403/04 ,  C07D401/04 ,  C07D403/14 ,  C07D409/12 ,  C07D405/12 ,  C07D409/04 ,  C07D413/04 ,  C07D409/14 ,  C07D403/12 ,  C07D405/06 ,  C07D409/06 ,  C07D471/04 ,  C07D217/24 ,  C07D401/12 ,  C07D417/04

CPC classification number: C07D209/46 ,  C07D209/48 ,  C07D217/24 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04

Abstract: Provided is a compound of formula (I) as a TNIK (Traf2- and NCK-interacting kinase), IKKε (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the compound according to the present invention effectively inhibits TNIK, IKKε and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

Abstract translation: 提供作为TNIK（Traf2-和NCK相互作用激酶），IKKε（I-κB激酶ε）和TBK1（TANK结合激酶1）抑制剂的式（I）化合物; 根据本发明的化合物有效地抑制TNIK，IKKε和TBK1，因此不仅可用作治疗各种癌症的抗癌剂，包括结肠直肠癌，乳腺癌，CNS癌，结肠癌，非小细胞肺癌 ，肾癌，前列腺癌，卵巢癌，子宫癌，胃癌，肝癌，皮肤癌，肺癌，脑癌，膀胱癌，食管癌，胰腺癌，甲状腺癌，头颈癌，鳞状细胞癌，骨肉瘤 ，B细胞或T细胞淋巴瘤，急性或慢性白血病和多发性骨髓瘤，但作为慢性炎症的治疗剂。

公开(公告)号：US20160145589A1

公开(公告)日：2016-05-26

申请号：US14976073

申请日：2015-12-21

Applicant: GREEN CROSS CORPORATION ,  MediGeneBio Corporation

Inventor： Thong-Gyu Jin ,  Yo Kyung Chung ,  Sang Hoon Paik ,  Yoo Chang Park ,  Jinwook Seo ,  Yong Woon Choi ,  Jong Mun Son ,  Yong-Chul Kim

IPC: C12N9/16

CPC classification number: C12N9/16 ,  A61K9/0019 ,  A61K38/465 ,  A61K47/02 ,  A61K47/26 ,  C12Y301/06013

Abstract: A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.

公开(公告)号：US09249397B2

公开(公告)日：2016-02-02

申请号：US14809856

申请日：2015-07-27

Applicant: GREEN CROSS CORPORATION ,  MediGeneBio Corporation

Inventor： Thong-Gyu Jin ,  Yo Kyung Chung ,  Sang Hoon Paik ,  Yoo Chang Park ,  Jinwook Seo ,  Yong Woon Choi ,  Jong Mun Son ,  Yong-Chul Kim

IPC: C12N9/16 ,  A61K38/46

CPC classification number: C12N9/16 ,  A61K38/465 ,  C12Y301/06013

Abstract: Disclosed are a composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for treating Hunter syndrome. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.

Abstract translation: 公开了包含重组异丙肾上腺素-2-硫酸酯酶（IDS）和治疗亨特综合征的方法的组合物。 IDS组合物的糖基化模式和甲酰甘氨酸含量与ELAPRASE®不同，具有优异的药物功效，比常规药剂更安全，因此可有效用于治疗亨特综合征。